- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04176965
Investigation of the Safety and Effectiveness of a Trifocal IOL
September 5, 2023 updated by: Beaver-Visitec International, Inc.
Clinical Investigation of the Safety and Effectiveness of FINEVISION HP Trifocal IOL
This study is a prospective, multicenter, randomized, double masked confirmatory trial comparing an investigational trifocal intraocular lens (IOL) and a commercially available monofocal IOL.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Detailed Description
The study will include adult subjects with operable cataracts in both eyes who are eligible for phacoemulsification cataract surgery followed by IOL implantation.
Study Type
Interventional
Enrollment (Estimated)
501
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Northridge, California, United States, 91325
- Mitchell C Shultz MD/Shultz Chang Vision
-
Orange, California, United States, 92868
- Coastal Vision Medical Group
-
-
Illinois
-
Orland Park, Illinois, United States, 60467
- Arbor Centers for Eye Care
-
-
Indiana
-
Indianapolis, Indiana, United States, 46240
- Michael Washburn Center for Ophthalmic Research
-
-
Minnesota
-
Alexandria, Minnesota, United States, 56308
- Vance Thompson Vision, MN Site
-
Bloomington, Minnesota, United States, 55420
- Chu Vision Institute
-
-
Missouri
-
Saint Louis, Missouri, United States, 63131
- Ophthalmology Consultants, Ltd
-
-
Montana
-
Bozeman, Montana, United States, 59718
- Vance Thompson Vision, MT Site
-
-
Nebraska
-
Omaha, Nebraska, United States, 68137
- Vance Thompson Vision NE Site
-
-
Nevada
-
Las Vegas, Nevada, United States, 89145
- Center For Sight
-
-
New Jersey
-
Vineland, New Jersey, United States, 08361
- Eye Associates & SurgiCenter
-
-
North Dakota
-
W. Fargo, North Dakota, United States, 58078
- Vance Thompson Vision ND Site
-
-
Ohio
-
Brecksville, Ohio, United States, 44141
- Cleveland Eye Clinic
-
-
Pennsylvania
-
West Mifflin, Pennsylvania, United States, 15122
- Associates in Ophthalmology Ltd
-
-
South Dakota
-
Sioux Falls, South Dakota, United States, 57108
- Vance Thompson Vision. SD Site
-
-
Texas
-
Dallas, Texas, United States, 75243
- Key-Whitman Eye Center
-
Nacogdoches, Texas, United States, 75965
- Lehmann Eye Center
-
San Antonio, Texas, United States, 78229
- Parkhurst NuVision
-
-
Utah
-
Salt Lake City, Utah, United States, 84107
- The Eye Institute of Utah
-
-
Virginia
-
Lynchburg, Virginia, United States, 24502
- Piedmont Eye Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Male or female adults, age 22 years or older at the Preoperative Visit.
- Visually significant cataracts in both eyes that are eligible for phacoemulsification cataract surgery.
- Willing to undergo cataract surgery in the second operative eye within 7 - 30 days after surgery in the first eye.
- Projected BCDVA of 0.2 logMAR (20/32 Snellen) or better in each eye after cataract surgery/IOL implantation, as determined by the medical judgement of the Investigator
- Eligible for receipt of an IOL power within the range of the investigational IOL (+10.0 D to +30.0 D, in 0.50 D increments) in each eye
Contact lens users must be willing to discontinue wear of their lenses in accordance with the following requirements:
- Rigid gas permeable lenses for ≥ 7 days prior to the Preoperative Visit
- Soft contact lenses for ≥ 3 days prior to the Preoperative Visit Contact lens wearers must demonstrate a stable refraction (within ±0.50 D for both sphere and cylinder) in each eye, as determined by manifest refraction on two consecutive examination dates at least one week apart after discontinuation of contact lens wear.
- Provide signed written consent prior to participation in any study-related procedures.
- Ability, comprehension, and willingness to follow study instructions, and likely to complete all study visits.
- Female subjects must be 1-year postmenopausal, surgically sterilized, or, if of childbearing potential, have a negative urine pregnancy test at the Preoperative Visit. Women of childbearing potential must use an acceptable form of contraception throughout the study. Acceptable methods include at least one of the following: intrauterine (intrauterine device), hormonal (oral, injection, patch, implant, ring), barrier with spermicide (condom, diaphragm), or abstinence.
Exclusion Criteria:
- History or presence of, or predisposition to, degenerative visual disorders (e.g., macular degeneration, retinal detachment, proliferative diabetic retinopathy, or other retinal disorders) predicted to result in BCDVA worse than 0.2 LogMAR (20/32 Snellen) in either eye during the study participation period.
- Significant anterior segment pathology in either eye that might increase intraoperative risk or compromise IOL stability (e.g., pseudoexfoliation syndrome)
- Reasonably expected to require secondary ocular surgical intervention or laser treatment other than YAG capsulotomy in either eye during the study participation period.
- Presence of one or more clinically significant corneal abnormalities in either eye, including corneal dystrophy, irregularity, or edema per the Investigator's medical opinion.
- Previous intraocular, corneal, or retinal detachment surgery, including corneal transplant, LASIK, astigmatic keratotomy and limbal relaxing incisions in either eye
- Rubella, congenital, traumatic or complicated cataract in either eye
- Preoperative keratometric astigmatism > 1.0 D or irregular corneal astigmatism in either eye (Note: corneal incisions intended to reduce astigmatism are not permitted)
- Clinically significant ocular inflammation or infection present ≤ 30 days in either eye prior to the Preoperative Visit.
- Presence or history of one or more severe/serious ocular conditions (e.g., glaucoma, uveitis, ocular infection, severe dry eye) in either eye, or any other unstable medical condition (e.g., uncontrolled diabetes) that in the opinion of the Investigator would put the subject's health at risk, confound the results of the study and/or prevent the subject from completing all study visits.
- Use of medications known to interfere with visual performance, pupil dilation, or iris structure ≤ 30 days prior to the Preoperative Visit.
- Participation in any study of an investigational, interventional product within 30 days prior to the Preoperative Visit or at any time during the study period.
- Pregnant or nursing females.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: FINEVISION HP
Trifocal FINEVISION HP.
Cataractous lens will be removed in the study eyes and the FINEVISION HP will be implanted in the capsular bag.
|
Cataractous lens will be removed in the study eyes and the FINEVISION HP IOL will be implanted in the capsular bag.
|
Active Comparator: Control Product
Cataractous lens will be removed in the study eyes and the Alcon AcrySof® SN60AT IOL will be implanted in the capsular bag.
|
Cataractous lens will be removed in the study eyes and the Alcon AcrySof SN60AT IOL will be implanted in the capsular bag.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Corrected distance visual acuity (BCDVA) in first operative eyes
Time Frame: 150-180 days after surgery on the first eye
|
Photopic monocular logMAR best corrected distance visual acuity (BCDVA) in first operative eyes at Month 6 (Visit 4)
|
150-180 days after surgery on the first eye
|
Distance corrected Near visual acuity (DCNVA) in first operative eyes
Time Frame: 150-180 days after surgery on the first eye
|
Photopic monocular logMAR distance corrected near visual acuity (DCNVA) in first operative eyes at Month 6 (Visit 4)
|
150-180 days after surgery on the first eye
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Distance corrected Intermediate visual acuity at 66 cm in first operative eyes
Time Frame: 150-180 days after surgery on the first eye
|
Mean photopic monocular DCVA at intermediate (66 cm) for the first operative eye at Month 6
|
150-180 days after surgery on the first eye
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 30, 2022
Primary Completion (Estimated)
November 9, 2023
Study Completion (Estimated)
November 9, 2023
Study Registration Dates
First Submitted
November 20, 2019
First Submitted That Met QC Criteria
November 22, 2019
First Posted (Actual)
November 26, 2019
Study Record Updates
Last Update Posted (Actual)
September 6, 2023
Last Update Submitted That Met QC Criteria
September 5, 2023
Last Verified
September 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- PHY1903
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Eye Diseases
-
University of Alabama at BirminghamPfizerCompletedVision | Eye Disease | Eye CareUnited States
-
TBF Genie TissulaireCompletedEnucleated; Eye | Eye CancerFrance
-
Kao (Taiwan) CorporationChang Gung Memorial HospitalCompletedEye Fatigue | Dry Eye SymptomTaiwan
-
National Eye Institute (NEI)RecruitingInherited Eye DiseaseUnited States, United Kingdom, China, Pakistan, Philippines, Ukraine, India, Italy
-
National Eye Institute (NEI)Recruiting
-
National Eye Institute (NEI)RecruitingGenetic Eye DiseaseUnited States
-
Assistance Publique - Hôpitaux de ParisCompleted
-
Assistance Publique - Hôpitaux de ParisCompleted
-
OptovueCompletedNo Eye DiseaseUnited States, United Kingdom
-
National Eye Institute (NEI)CompletedHereditary Eye DiseaseUnited States
Clinical Trials on FINEVISION HP IOL
-
Enrique Ordiñaga-Monreal, OD, MScUnknownAstigmatism | Visual Acuity | IOL | Cataract AfterSpain
-
Alexandria UniversityCompletedRefractive ErrorsEgypt
-
Beaver-Visitec International, Inc.CompletedCataract | Lens OpacityAustralia
-
Beaver-Visitec International, Inc.Withdrawn
-
Beaver-Visitec International, Inc.Completed
-
Peking University Third HospitalPeople's Hospital of GuangxiRecruitingPresbyopia | Cataract SenileChina
-
Fundació Institut de Recerca de l'Hospital de la...Programa de Reproducción Asistida F. Puigvert - HSCSPTerminatedPolycystic Ovary SyndromeSpain
-
University of TriesteCompleted
-
Peking University Third HospitalUnknown
-
LG ChemCompletedInfertility, FemaleKorea, Republic of